Insurance coverage varies for both and depends on your specific plan and indication
The gap between the ad and reality is significant
Semaglutide is currently the most prominent approved option in this class: Ozempic (semaglutide injection) licensed for type 2 diabetes management Wegovy (semaglutide 2.4 mg injection) licensed specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
Contraindications: - Personal or family history of medullary thyroid carcinoma (MTC) - Multiple Endocrine Neoplasia syndrome type 2 (MEN2) - Serious hypersensitivity to orforglipron Safety profile: Common adverse effects include nausea, diarrhea, constipation, vomiting, abdominal pain, and fatigue
: -006910 09.04.21 : 27.07.23 NOVO NORDISK () : () 0.25 / : -(014579)-(-RU) 22.04.26 : -008872 0.5 / : -(014579)-(-RU) 22.04.26 : -008872 1 / : -(014579)-(-RU) 22.04.26 : -008872 - () : HANGZHOU ZHONGMEI HUADONG PHARMASEUTICAL () 0.25/0.5/1 / : -008876 05.09.25 - () : NANJING KINGFRIEND BIOCHEMICAL PHARMACEUTICAL () 1.34 /1 : - 3 (0.25 /0.5 /1 /1 ) : -(008022)-(-RU) 09.12.24 : 15.04.25 : -008825 () 0.25 / : -(007099)-(-RU) 03.10.24 0.5 / : -(007099)-(-RU) 03.10.24 1 / : -(007099)-(-RU) 03.10.24 1.7 / : -(007099)-(-RU) 03.10.24 2.4 / : -(007099)-(-RU) 03.10.24 () 0.25/0.5 /: - 1.5 1 5
News-Medical, viewed 28 July 2026, Suggested Reading